COMMUNIQUÉS West-GlobeNewswire

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
19/05/2025
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as [...]
Medera Showcased Positive Interim Data From First-in-Human Gene Therapy Trial for HFpEF in Late-Breaking Presentation at Heart Failure 2025 Congress
19/05/2025
Results from MUSIC-HFpEF Phase 1/2a clinical trial show favorable safety profile and early clinical benefits with SRD-002 gene therapy BOSTON, May 19, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage [...]
Alignment Health Plan Recognized as One of Two Medicare Advantage Prescription Drug Plans in the U.S. for Excellence in Pharmacy Quality
19/05/2025
Pharmacy Quality Alliance award reaffirms Alignment’s commitment to medication adherence and pharmacy excellence for seniors ORANGE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) has [...]
Eascra Biotech Awarded $100,000 MassVentures START Grant
19/05/2025
Funding to Improve Treatments and Outcomes of Hard-to-treat Conditions BOSTON, May 19, 2025 (GLOBE NEWSWIRE) -- Eascra Biotech, a nanomedicine startup, has been awarded a $100,000 Stage I SBIR Targeted Technologies ( [...]
Rani Therapeutics Announces Research Agreement with Chugai
19/05/2025
- Research agreement is evaluating feasibility of applying Rani’s oral delivery technology to Chugai’s antibodies against undisclosed targets - SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics [...]
Respira Therapeutics Announces Late-breaking Presentation of RT234 Phase 2b PAH Clinical Trial Results at the American Thoracic Society (ATS) 2025 International Conference
19/05/2025
PALO ALTO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Respira Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing RT234 (vardenafil inhalation powder) as the first therapy that pulmonary [...]
CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma
19/05/2025
SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the first patient has been [...]
Reflect Scientific Strengthens Position in Booming AI Data Center Cooling Market with Patented Cryogenic Innovations
19/05/2025
OREM, Utah, May 19, 2025 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a pioneer in cryogenic cooling technologies, today highlighted how its patented solutions are uniquely positioned to address the [...]
Bionano Laboratories Announces a Second Category I CPT Code for OGM Established by the AMA; this one for Use in Whole Genome Analysis for Constitutional Genetic Disorders
19/05/2025
SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based on optical genome [...]
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
19/05/2025
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis largely balanced and representative of targeted trial population. Real-world evidence [...]
STRATA Skin Sciences Announces Historic Expansion of CPT Codes for Reimbursement of 308nm Excimer Laser Treatments, Unlocking Access for Millions with Inflammatory and Auto-Immune Skin Diseases
19/05/2025
HORSHAM, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to advancing dermatologic care through innovation, announces [...]
Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value
19/05/2025
Files Investor Presentation and Issues Open Letter to Stockholders Urges Stockholders to Protect the Value of Their Investment by Voting “FOR” Each of the Company’s Highly Qualified Director Nominees LEXINGTON, Mass., [...]
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
19/05/2025
Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy [...]
SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology
19/05/2025
Lexicon is evaluating the safety and efficacy of sotagliflozin in patients with both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) Pivotal Phase 3 clinical trial is actively enrolling patients in 20 [...]
Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
19/05/2025
SOMERSET, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, June 1, 2025, at 6:00 [...]
Transactions under Novonesis’ share buyback program
19/05/2025
Please read the announcement in PDF Attachment 2025_25_Share_buyback_program
Reunion Neuroscience Announces Last Patient Dosed in RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)
19/05/2025
-- Enrollment Completed on Schedule; Topline Results Expected Q3 2025 -- -- Company to Present Poster Reviewing RE104 Phase 1 Results at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting on May [...]
Atsena Therapeutics Announces Positive Clinical Data from Part A of Phase I/II Trial Evaluating ATSN-201 Gene Therapy to Treat X-linked Retinoschisis (XLRS)
19/05/2025
First XLRS study to demonstrate efficacy and positive safety data in a Phase I/II trial Majority of patients demonstrated successful efficacy readouts across structural measurements (foveal schisis closure) and had [...]
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
19/05/2025
GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, [...]

Pages